Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome (34-DAP)
Compassionate use of orphan drug 3,4-Diaminopyridine(DAP) in Treatment of Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP is used to decrease the muscle weakness associated with LEMS and hopefully will decrease the need for prednisone and all other therapies that were previously required to control symptoms. How long a patient will take 3,4 DAP depends upon if he/she is seeing benefits from the medication or experiencing side effects that will prevent them from continuation in the study.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome|
|Study Start Date:||September 1997|
|Estimated Primary Completion Date:||September 2012 (Final data collection date for primary outcome measure)|
Drug: 3,4 DAP
3,4-diaminopyridine (3,4-DAP) decreases symptoms of weakness in patients with LEMS, and therefore can be used to decrease the amount of immune modulation therapy needed to provide an equivalent degree of disease control.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01373333
|Contact: Sneha Rameshfirstname.lastname@example.org|
|United States, Ohio|
|Cleveland Clinic Foundation|
|Cleveland, Ohio, United States, 44139|
|Contact: Sneha Ramesh 216-445-8597 email@example.com|
|Principal Investigator: Kerry H Levin, M.D.|
|Principal Investigator:||Kerry H Levin, M.D.||The Cleveland Clinic|